<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330434</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAGRE15647</org_study_id>
    <secondary_id>F32AA015647-01A1</secondary_id>
    <secondary_id>1F32AA015647-01A1</secondary_id>
    <nct_id>NCT00330434</nct_id>
  </id_info>
  <brief_title>Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism</brief_title>
  <official_title>Human CYP2B6: Induction by Ethanol and Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The two purposes of this study are&#xD;
&#xD;
        1. to determine what effect the chronic and moderate/heavy drinking of alcoholic beverages&#xD;
           has&#xD;
&#xD;
             1. on the blood level of bupropion and chlorzoxazone and their major breakdown&#xD;
                products in the blood and&#xD;
&#xD;
             2. on the stimulant effect of bupropion and&#xD;
&#xD;
        2. to determine what effect a normal and common (25% frequency) genetic variation of a&#xD;
           specific liver enzyme (that breaks down bupropion) has&#xD;
&#xD;
             1. on the blood levels of bupropion and its major breakdown products in the blood and&#xD;
&#xD;
             2. on the stimulant effect of bupropion.&#xD;
&#xD;
      Two groups of volunteers will be recruited for this study:&#xD;
&#xD;
        1. volunteers who drink moderate to heavy amounts of alcohol frequently and&#xD;
&#xD;
        2. volunteers who usually do not drink alcohol.&#xD;
&#xD;
      Volunteers will NOT be asked to change their drinking (or nondrinking) habits during the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was a F32 Fellowship. Trial was proposed however Principle Investigator does not believe&#xD;
    trial took place.&#xD;
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Alcohol Drinking</condition>
  <condition>Depression</condition>
  <condition>Smoking Cessation</condition>
  <condition>Attention Deficit Disorder</condition>
  <arm_group>
    <arm_group_label>Trial Withdrawn 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trial Withdrawn 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial Withdrawn 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trial Withdrawn 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Trial Withdrawn 1</intervention_name>
    <description>Trial Withdrawn 1</description>
    <arm_group_label>Trial Withdrawn 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Trial Withdrawn 2</intervention_name>
    <description>Trial Withdrawn 2</description>
    <arm_group_label>Trial Withdrawn 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults who are 21 - 55 years of age.&#xD;
&#xD;
          -  Either 1) Moderate-to-heavy drinkers who drink on average more than 14 but less than&#xD;
             28 drinks per week; OR 2) adults who normally abstain from drinking alcohol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants who are currently taking prescription medications (including oral&#xD;
             contraceptives)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body mass index (BMI) greater than 30&#xD;
&#xD;
          -  History of seizures or eating disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Greenblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University; Chair of Department of Pharmacology and Experimental Therapeutics, Sackler School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael H. Court, BVsc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University, Department of Pharmacology and Experimental Therapeutics, Sackler School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos. 2000 Oct;28(10):1176-83.</citation>
    <PMID>10997936</PMID>
  </reference>
  <reference>
    <citation>Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004 Apr;14(4):225-38. Erratum in: Pharmacogenetics. 2005 Apr;15(4):265.</citation>
    <PMID>15083067</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 25, 2006</study_first_submitted>
  <study_first_submitted_qc>May 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alcohol</keyword>
  <keyword>Bupropion</keyword>
  <keyword>Chlorzoxazone</keyword>
  <keyword>Interaction</keyword>
  <keyword>Induction</keyword>
  <keyword>Depression</keyword>
  <keyword>Smoking</keyword>
  <keyword>Drinking</keyword>
  <keyword>Cytochrome P450 Enzyme</keyword>
  <keyword>CYP2B6</keyword>
  <keyword>CYP2E1</keyword>
  <keyword>Pharmacogenetics</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Boston</keyword>
  <keyword>Tufts University</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

